Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

This is a single-center, non-randomized, single-arm, open-label study, in which adults with episodic or chronic migraine will receive intravenous infusion with calcitonin gene-related peptide and subsequently be treated with erenumab. The study will consist of the following elements: * Provocation Phase (1 experimental day with intravenous infusion of calcitonin gene-related peptide) * Screening/Baseline Phase (4 weeks) * Open-Label Treatment Phase (24 weeks)